NCT07433179
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SEP-479 in Healthy Adult Participants
概览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Frequency of treatment emergent adverse events
概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-479 in healthy adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 21 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who are able and willing to provide informed consent
- •Aged 21 to 60 years at the time of consent
- •Have a BMI within the range 18.0 to 32.0 kg/m2
- •In general good health
排除标准
- •Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
- •Have clinically significant abnormalities on clinical laboratory results.
- •Participation in other clinical trials recently/currently
研究组 & 干预措施
Single Ascending Dose
Experimental
干预措施: SEP-479 (Drug)
Single Ascending Dose
Experimental
干预措施: Placebo (Other)
Multiple Ascending Dose
Experimental
干预措施: SEP-479 (Drug)
Multiple Ascending Dose
Experimental
干预措施: Placebo (Other)
Food Effect
Experimental
干预措施: SEP-479 (Drug)
结局指标
主要结局
Frequency of treatment emergent adverse events
时间窗: From enrollment to end of follow up visit, up to approximately 2 months
次要结局
- Plasma PK of SEP-479 after single and multiple doses(From enrollment to end of treatment period, up to approximately 14 days)
- Plasma PK of SEP-479 under fed and fasted conditions(From enrollment to end of treatment period, up to approximately 14 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy SubjectsNCT07304791Beam Therapeutics Inc.30
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
招募中
早期 1 期
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCNCT07355972Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12
招募中
1 期
A Study to Evaluate ALN-4285 in Adult Healthy VolunteersNCT07295717Alnylam Pharmaceuticals76
招募中
早期 1 期
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune DiseasesNCT07333118Grit Biotechnology22